Focus: Actuate Therapeutics is a publicly traded oncology-focused biotech company developing small-molecule cancer therapeutics. The company operates at a micro-cap scale with a lean pipeline in early-to-mid stage development.
Profile data last refreshed 8h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Actuate Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Actuate Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Actuate Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
+2 more
Actuate Therapeutics (ACTU) Falls 6.35% to $1.18 as Shares Test Lower Support - High Reward Trades - dars.gov.et
Actuate Therapeutics (ACTU) Falls 6.35% to $1.18 as Shares Test Lower Support - High Reward Trades dars.gov.et
Actuate Therapeutics Reports Synergistic Preclinical Activity of Elraglusib with RAS-Targeted Agents in Pancreatic Cancer Models - Quiver Quantitative
Actuate Therapeutics Reports Synergistic Preclinical Activity of Elraglusib with RAS-Targeted Agents in Pancreatic Cancer Models Quiver Quantitative
All You Need to Know About Actuate Therapeutics, Inc. (ACTU) Rating Upgrade to Buy - Yahoo Finance
All You Need to Know About Actuate Therapeutics, Inc. (ACTU) Rating Upgrade to Buy Yahoo Finance
Actuate Therapeutics (ACTU) Holds $1.00 After 1.31% Gain, Pinned Between Key Support and Resistance - Inverse ETF Flow - dars.gov.et
Actuate Therapeutics (ACTU) Holds $1.00 After 1.31% Gain, Pinned Between Key Support and Resistance - Inverse ETF Flow dars.gov.et
Actuate Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary - TradingView
Actuate Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary TradingView
Actuate Therapeutics (ACTU) CEO RSUs Vest, 120,521 Shares Withheld for Taxes - Stock Titan
Actuate Therapeutics (ACTU) CEO RSUs Vest, 120,521 Shares Withheld for Taxes Stock Titan
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo